Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr Moser on the SUPRAME Trial of IMA203 in Pretreated Cutaneous Melanoma

June 25th 2025

Justin Moser, MD, discusses the design and implications of the SUPRAME trial investigating IMA203 in pretreated advanced cutaneous melanoma.

Rusfertide Significantly Reduces Therapeutic Phlebotomy Necessity in Polycythemia Vera

June 25th 2025

Andrew Kuykendall, MD, discusses the utility of rusfertide in reducing therapeutic phlebotomy eligibility in patients with polycythemia vera.

Dr Kuykendall on the Rationale for Targeting the Hepcidin Pathway With Rusfertide in Polycythemia Vera

June 24th 2025

Andrew Kuykendall, MD, discusses the rationale for using rusfertide to target the hepcidin pathway in patients with polycythemia vera.

5-Year Analysis of KEYNOTE-564 Reinforces Role of Adjuvant Pembrolizumab as SOC in ccRCC

June 24th 2025

Naomi B. Haas, MD, delves into the KEYNOTE-564 trial and highlights the role of adjuvant pembrolizumab in clear cell renal cell carcinoma.

Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC

June 24th 2025

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Dr Janjigian on the Efficacy of Durvalumab Plus Chemotherapy in Resectable GEJ Adenocarcinoma

June 24th 2025

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

Gecacitinib Elicits Hematologic Responses, Spleen and Symptom Reduction Across Anemic Subgroups in Myelofibrosis

June 23rd 2025

Gecacitinib, a dual JAK/ACVR1 inhibitor, showed spleen volume, symptom and anemia improvements in patients with myelofibrosis.

Paulus on the Rationale for Utilizing an External Control Arm in a Single-Arm HER2+ Breast Cancer Trial

June 23rd 2025

Jessica Paulus, ScD, explains the rationale for utilizing an external control arm in a single-arm phase 2 HER2-positive metastatic breast cancer trial.

Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain Metastases

June 23rd 2025

Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.

Dr Morgans on HRQOL Outcomes With Darolutamide Plus ADT in mHSPC

June 23rd 2025

Alicia Morgans, MD, MPH, discusses health-related quality of life outcomes with darolutamide plus ADT in patients with mHSPC.

Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma

June 23rd 2025

Surbhi Sidana, MD, highlighted the continued efficacy of cilta-cel in patients with relapsed/refractory multiple myeloma, according to an ITT analysis.

UM171 Cell Therapy Earns Positive CHMP Opinion for Hematological Malignancies

June 20th 2025

The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.

Nirogacestat Awaits Review Following Positive CHMP Opinion for Desmoid Tumors

June 20th 2025

The EMA’s Committee for Medicinal Products for Human Use granted a positive opinion for nirogacestat for the treatment of patients with desmoid tumors.

CHMP Recommends EU Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

June 20th 2025

The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Dr Ghia on the Efficacy of Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

June 20th 2025

Paolo Ghia, MD, PhD, discusses the efficacy of fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL.

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

June 19th 2025

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC

June 19th 2025

Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.

Dr Jones on the Evolving Treatment Landscape in GIST

June 19th 2025

Robin Jones, MD, MRCP, discusses the treatment armamentarium for patients with gastrointestinal stromal tumors.

Dr DeAngelo on Challenges With Utilizing Pediatric-Inspired Regimens in Adult and AYA ALL

June 19th 2025

Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyper‐CVAD in adult and AYA patients with ALL.

Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD

June 19th 2025

Dr Danilov highlights advances and questions in the management of mantle cell lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma.

x